TRxADE HEALTH, Inc. (MEDS) Key Metrics
MEDS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $11.9M
- Enterprise value
- $42.6M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 1.5
- Price / book
- 80.9
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
MEDS key metrics, 2022–2025
Fiscal year ended December 31, 2025 · U.S. dollarsMEDS returns How much profit the business earns on the capital it uses.
MEDS per-share figures Results divided by the shares outstanding at year-end.
MEDS financial health Debt, liquidity and how easily interest is covered.
MEDS efficiency & capital use Working capital cycle and where the cash goes.
MEDS valuation history
MEDS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
MEDS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
MEDS price vs earnings per share
MEDS key metrics
2022–2025| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Valuation | ||||
| Market capitalization | $28.4M | — | — | — |
| Enterprise value | $53.1M | — | — | — |
| Price / sales | 1.2 | — | — | — |
| EV / sales | 2.3 | — | — | — |
| Earnings yield | −357.1% | — | — | — |
| Free cash flow yield | −38.3% | — | — | — |
| Share price at fiscal year-end | $19.98 | — | — | — |
| Per share | ||||
| Revenue per share | $16.44 | $17.45 | — | $34.68 |
| Earnings per share | −$71.33 | −$6.60 | — | −$2.90 |
| Operating cash flow per share | −$7.65 | −$1.18 | — | $0.00 |
| Free cash flow per share | −$7.65 | −$1.54 | — | $0.00 |
| Cash per share | $0.03 | $0.99 | — | — |
| Book value per share | −$8.77 | $6.48 | — | −$0.01 |
| Tangible book value per share | −$26.03 | −$30.65 | — | −$0.01 |
| Capex per share | $0.62 | $0.36 | — | $0.00 |
| Debt per share | $17.45 | $24.17 | — | — |
| Shares outstanding | 1.4M | 1.0M | — | 945K |
| Change in shares outstanding | +36.6% | — | — | — |
| Returns & profitability | ||||
| Return on equity (ROE) | — | −357.7% | — | — |
| Return on invested capital (ROIC) | −297.7% | −33.9% | — | — |
| Return on assets (ROA) | −230.7% | −23.8% | — | — |
| Return on tangible assets | — | −36.6% | −855.8% | — |
| Free cash flow margin | −46.5% | −8.8% | — | 0.0% |
| Financial health | ||||
| Total debt | $24.8M | $25.1M | $700,000 | — |
| Cash & short-term investments | $42,571 | $1.0M | $1,364 | — |
| Net debt | $24.7M | $24.1M | $698,636 | — |
| Debt / equity | — | 3.73 | — | — |
| Debt / assets | 0.81 | 0.44 | 2.07 | — |
| Current ratio | 0.09 | 0.40 | 0.12 | 0.00 |
| Quick ratio | 0.04 | 0.15 | 0.12 | 0.00 |
| Interest coverage | -17.7 | -7.4 | -191.0 | -11.9 |
| Working capital | −$27.0M | −$22.9M | −$2.6M | −$5,250 |
| Invested capital | $12.3M | $30.8M | −$2.2M | −$5,250 |
| Tangible asset value | −$37.0M | −$31.8M | −$2.9M | −$5,250 |
| Net current asset value | −$40.1M | −$35.4M | −$2.9M | −$5,250 |
| Graham net-net per share | −$29.01 | −$40.42 | — | −$0.01 |
| Capital allocation | ||||
| Capex / revenue | 3.8% | 2.1% | — | 0.0% |
| Capex / depreciation | 0.27 | 0.34 | — | 0.00 |
| Stock-based compensation / revenue | 234.8% | 6.0% | — | — |
| R&D / revenue | — | — | — | 0.0% |
| SG&A / revenue | 306.6% | 37.5% | — | 21.6% |
| Efficiency | ||||
| Days sales outstanding | 38.2 | 41.1 | — | — |
| Days of inventory on hand | 61.8 | 106.2 | — | — |
| Days payables outstanding | 99.8 | 82.2 | — | 0.1 |
| Cash conversion cycle (days) | 0.2 | 65.0 | — | — |
| Receivables turnover | 9.56 | 8.88 | 0.00 | — |
| Payables turnover | 3.66 | 4.44 | 0.00 | 5,148.36 |
| Inventory turnover | 5.91 | 3.44 | — | — |
| Asset turnover | 0.53 | 0.63 | 0.00 | — |
| Average receivables | $2.4M | $2.0M | $337,000 | — |
| Average payables | $9.0M | $3.7M | $521,961 | $5,250 |
| Average inventory | $5.6M | $4.8M | $0 | — |
| Intangibles / total assets | 80.5% | 67.3% | 0.0% | — |
Computed from MEDS's annual financial statements (latest annual report filed March 20, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
MEDS valuation and financial ratios
TRxADE HEALTH earned a return on invested capital of −297.7% in fiscal 2025. It ended the year with $24.8 million of debt and $0.0 million in cash and short-term investments, net debt of $24.7 million.
See the MEDS income statement, the MEDS chart for price history, or the MEDS stock overview for the latest quote and news.
MEDS key metrics FAQ
What is TRxADE HEALTH's ROIC?
TRxADE HEALTH's return on invested capital was −297.7% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does TRxADE HEALTH have?
TRxADE HEALTH had total debt of $24.8 million at the end of fiscal 2025.
What is TRxADE HEALTH's free cash flow yield?
TRxADE HEALTH generated -$10.9 million of free cash flow in fiscal 2025, a free cash flow yield of −38.3% on its market value at year-end ($28.4 million).
What is TRxADE HEALTH's current ratio?
TRxADE HEALTH's current ratio was 0.09 at the end of fiscal 2025: current assets were 0.09 times current liabilities.